期刊
AGING-US
卷 13, 期 10, 页码 14304-14321出版社
IMPACT JOURNALS LLC
DOI: 10.18632/aging.203045
关键词
clear cell renal cell carcinoma; CD45RO+CD8+T cells; biomarker; UCHL1
资金
- Natural Science Foundation of China [81672515, 81972393, 81772705]
- Shanghai Pujiang Program [16PJD039]
- Commission of Gaofeng Clinical Medicine Grant [20172019]
Research indicates that CD45RO+CD8+ T cells play a critical role in inhibiting the progression of clear cell renal carcinoma (ccRCC) through multiple signaling pathways, demonstrating significant clinical importance as potential indicators in ccRCC patients.
Renal cell carcinoma is characterized by high immunogenicity and infiltration of immune cells. CD45RO+CD8+ T cells are well known as a critical role in host defense of the immune environment. However, their role in clear cell renal carcinoma (ccRCC) remains unknown. To elucidate the clinical importance of CD45RO+CD8+ T cells in ccRCC as well as its underlying mechanism, we analyzed several types of peripheral immune cells from 274 patients with ccRCC who have received radical or partial nephrectomy and 350 healthy people. Flow cytometry assays showed there was no significant difference in the proportions of CD8+ T cells and its subtypes other than CD45RO+/CD45RA+CD8+ cells. Both gene and protein expression levels of CD45RO in ccRCC tissues were decreased. CD45RO+CD8+ T cells showed increased proliferative abilities but decreased apoptotic abilities through MAPK signaling activation in ccRCC. High expression level of CD45RO+CD8+ T cells inhibited ccRCC progression, including proliferation, invasion, as well as autophagy of ccRCC through many signaling pathways. Bioinformatics and immunohistochemical chip analysis measured gene and protein levels of CD45RO and other related proteins. The combination of UCHL1, HMGB3, and CD36 has diagnostic value in ccRCC and is able to predict prognosis. Collectively, CD45RO+CD8+ T cells play a critical role in ccRCC progression and may be regarded as clinical indicators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据